Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia.
We describe and discuss the process of clinical translation, including the design of a cell manufacturing protocol, vector production and regulatory issues. Multiple antigen targeting and combination of CAR T cells with molecular targeted drugs have also been evaluated as latest strategies to prevail over immune-evasion.
PMID: 28843422 [PubMed - as supplied by publisher]
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: Biondi A, Magnani CF, Tettamanti S, Gaipa G, Biagi E Tags: J Autoimmun Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Childhood Cancer | Children | Genetics | Immunotherapy | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants | Vaccines